Across TCGA pan-cancer cohorts, ADAMTS5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMTS5 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ADAMTS5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAMTS5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, ESCA, and LIHC are the cancer types where ADAMTS5 Mutation most reproducibly stratifies survival.